SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
24.20
+1.15 (4.99%)
Oct 31, 2025, 12:59 PM CET
4.99%
Market Cap1.29B
Revenue (ttm)n/a
Net Income (ttm)-106.28M
Shares Out53.33M
EPS (ttm)-2.20
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume163,217
Average Volume162,378
Open23.00
Previous Close23.05
Day's Range22.85 - 24.60
52-Week Range7.31 - 25.30
Beta1.14
RSI61.09
Earnings DateOct 30, 2025

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.